CSL Behring Medical Expert Portal is a European webpage designed for healthcare professionals (HCPs) who are interested in serious and life-threatening conditions. Register and login to access the information on this webpage and to receive updates when new content becomes available. If you are interested in the relevant content for a specific country, please refer to the CSL Behring affiliate in your country to obtain relevant information. The medical and scientific information provided on this website is for informational purposes only and should not replace professional advice from a healthcare provider in your area. It is important that you always adhere to the regulations and guidelines relevant to your country.

Disclaimer: Due to compliance regulations, not all content of this webpage is intended for UK healthcare practitioners. If you would like to access UK specific materials on this site, please reach out to your local CSL Behring medical representative (medinfo@cslbehring.com) for assistance.

Disclaimer

CSL EXPERT HIVE

Symposia replays

Gene therapy in haemophilia: the evolving patient-centric multidisciplinary journey

Pathology:

Haemophilia A Haemophilia B

EAHAD, 16th Annual Congress, February 7–10, 2023

Watch the full video recording of the CSL Behring symposium held on February 8, 2023.

This unique and interactive symposium was moderated by Michiel Coppens (The Netherlands) and featured discussions with Daan Breederveld, Lotte Haverman (The Netherlands) and Graham Foster and Kate Khair (UK).

A multidisciplinary panel of experts outlined the patient journey through life with haemophilia. Starting with a summary of the current haemophilia treatment landscape, the faculty discussed the patient experience of growing up with haemophilia and highlighted the unmet needs of patients and their families. The faculty also discussed the shared decision-making process between patients considering gene therapy and their multidisciplinary team members, and the potential changes to multidisciplinary care after gene therapy.

Please note that this symposium contains information on specific products and indications, including discussion of products in late-stage clinical trials which are not currently licenced.